Abstract
Incretin therapy has shown good clinical efficacy and safety. Cardiovascular risk reduction induced by this therapy is in line with the results of the first meta-analyses of the previous clinical trials that have reported significant reduction of cardiovascular risk.
If these results are confirmed by prospective studies, incretin will become first-line therapy in addition to metformin.